Aceña Álvaro, Pello-Lázaro Ana María, Martínez-Milla Juan, González-Lorenzo Óscar, Tarín Nieves, Cristóbal Carmen, Blanco-Colio Luis M, Martín-Ventura José Luis, Huelmos Ana, López-Castillo Marta, Alonso Joaquín, Gutiérrez-Landaluce Carlos, López Bescós Lorenzo, Alonso-Pulpón Luis, González-Parra Emilio, Egido Jesús, Mahíllo-Fernández Ignacio, Lorenzo Óscar, González-Casaus María Luisa, Tuñón José
Departamento de Cardiología, IIS-Fundación Jiménez Díaz, Madrid, España; Universidad Autónoma de Madrid, Madrid, España.
Departamento de Cardiología, IIS-Fundación Jiménez Díaz, Madrid, España.
Clin Investig Arterioscler. 2022 Jan-Feb;34(1):1-9. doi: 10.1016/j.arteri.2021.09.003. Epub 2021 Dec 4.
Parathormone (PTH) is a component of the Mineral Metabolism (MM) system that has been shown recently to add prognostic value in pts. with stable coronary artery disease (SCAD) and average renal function. However, the influence of renal function on the prognostic role of PTH in pts. with SCAD has not been shown yet.
To assess the influence of estimated glomerular filtration rate (eGFR) on the prognostic role of PTH and other MM markers in pts. with SCAD.
We analyzed the prognostic value of MM markers (PTH, klotho, phosphate, calcidiol [25-hydroxyvitamin D], and fibroblast growth factor-23 [FGF23]) in 964 pts. with SCAD and eGFR<60ml/min/1.73 m (LGFR) vs pts. with eGFR≥60ml/min/1.73 m (HGFR) included in five hospitals of Madrid. The main outcome was the combination of death with ischemic events (any acute coronary syndrome, ischemic stroke or transient ischemic attack). eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration equation (CKD-EPI).
Age was 60.0 (52.0-72.0) years, 76.2% of patients were men, and eGFR was 80.4 (65.3-93.1) ml/min/1,73 m. Median follow-up was 5.39 (2.81-6.92) years. There were 790 pts. with HGFR and 174 with LGFR. In HGFR pts., predictors of ischemic events or death were plasma levels of calcidiol [HR=0.023 (0.94-0.99) p=0.023], FGF23 [HR=1.00 (1.00-1.003) p=0.036], non-HDL cholesterol [HR=1.01 (1.00-1.01) p=0.026] and high sensitivity troponin I [HR=5.12 (1.67-15.59) p=0.004], along with age [HR=1.03 (1.01-1.05) p=0.01], treatment with statins [HR=0.36 (0.19-0.68) p=0.002], nitrates [HR=1.13 (1.07-2.79) p=0.027], dihydropyridines [HR=1.71 (1.05-2.77) p=0.032], verapamil [HR=5.71 (1.35-24.1) p=0.018], and proton-pump inhibitors [HR=2.23 (1.36-3.68) p= 0.002]. In the LGFR subgroup, predictors of death or ischemic events were PTH plasma levels, [HR=1.01 (1.00-1.01) p=0.005], eGFR [HR=0.96 (0.94-0.99) p=0.004], age [HR=1.06 (1.02-1.10) p=0.003], caucasian race [HR=0.04 (0.004-0.380) p=0.005], and treatment with insulin [HR=2.6 (1.20-5.63) p=0.015].
In pts. with SCAD, PTH is an independent predictor of poor outcomes only in those with eGFR<60ml/min/1.73 m, while in pts. with eGFR≥60ml/min/1.73 m calcidiol and FGF23 become the only components of MM that may predict prognosis. Then, renal function influences the predictive power of MM markers in pts. with SCAD.
甲状旁腺激素(PTH)是矿物质代谢(MM)系统的一个组成部分,最近已证明其在稳定型冠状动脉疾病(SCAD)且肾功能正常的患者中具有预后价值。然而,肾功能对PTH在SCAD患者中的预后作用的影响尚未明确。
评估估算肾小球滤过率(eGFR)对PTH及其他MM标志物在SCAD患者中的预后作用的影响。
我们分析了964例SCAD患者中MM标志物(PTH、klotho、磷酸盐、骨化二醇[25-羟基维生素D]和成纤维细胞生长因子-23 [FGF23])的预后价值,这些患者的估算肾小球滤过率(eGFR)<60ml/min/1.73m²(低肾小球滤过率[LGFR]),并与马德里五家医院纳入的eGFR≥60ml/min/1.73m²(高肾小球滤过率[HGFR])的患者进行比较。主要结局是死亡与缺血事件(任何急性冠状动脉综合征、缺血性中风或短暂性脑缺血发作)的联合。eGFR通过慢性肾脏病流行病学协作组方程(CKD-EPI)计算。
年龄为60.0(52.0 - 72.0)岁,76.2%的患者为男性,eGFR为80.4(65.3 - 93.1)ml/min/1.73m²。中位随访时间为5.39(2.81 - 6.92)年。有790例高肾小球滤过率患者和174例低肾小球滤过率患者。在高肾小球滤过率患者中,缺血事件或死亡的预测因素是骨化二醇的血浆水平[风险比(HR)=0.97(0.94 - 0.99),P = 0.023]、FGF23 [HR = 1.00(1.00 - 1.003),P = 0.036]、非高密度脂蛋白胆固醇[HR = 1.01(1.00 - 1.01),P = 0.026]和高敏肌钙蛋白I [HR = 5.12(1.67 - 15.59),P = 0.004],以及年龄[HR = 1.03(1.01 - 1.05),P = 0.01]、他汀类药物治疗[HR = 0.36(0.19 - 0.68),P = 0.002]、硝酸盐类药物[HR = 1.13(1.07 - 2.79),P = 0.027]、二氢吡啶类药物[HR = 1.71(1.05 - 2.77),P = 0.032]、维拉帕米[HR = 5.71(1.35 - 24.1),P = 0.018]和质子泵抑制剂[HR = 2.23(1.36 - 3.68),P = 0.002]。在低肾小球滤过率亚组中,死亡或缺血事件的预测因素是PTH血浆水平[HR = 1.01(1.00 - 1.01),P = 0.005]、eGFR [HR = 0.96(0.94 - 0.99),P = 0.004]、年龄[HR = 1.06(1.02 - 1.10),P = 0.003]、白种人[HR = 0.04(0.004 - 0.380),P = 0.005]和胰岛素治疗[HR = 2.6(1.20 - 5.63),P = 0.015]。
在SCAD患者中,PTH仅在估算肾小球滤过率<60ml/min/1.73m²的患者中是不良结局的独立预测因素,而在估算肾小球滤过率≥60ml/min/1.73m²的患者中,骨化二醇和FGF23成为MM中唯一可预测预后的成分。因此,肾功能会影响MM标志物在SCAD患者中的预测能力。